BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Bofanglutide readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Bofanglutide\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07150975-190@assetmemo.bio
DTSTAMP:20261121T004047Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Bofanglutide: Phase 3 readout est. (NCT07150975)
DESCRIPTION:Bofanglutide\, phase 3\, Obesity.\nStudy: Phase III Clinical St
 udy Comparing the Efficacy and Safety of GZR18 Injection and Semaglutide (
 Wegovy®) in Adult Obese or Overweight Subjects\nEstimated primary complet
 ion: 30 June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bo
 fanglutide#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07150975
URL:https://assetmemo.bio/drug/bofanglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07628985-190@assetmemo.bio
DTSTAMP:20261121T004047Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Bofanglutide: Phase 3 readout est. (NCT07628985)
DESCRIPTION:Bofanglutide\, phase 3\, Type 2 Diabetes.\nStudy: BALANCE-DM2 S
 tudy of Bofanglutide in Adults With Type 2 Diabetes\nEstimated primary com
 pletion: October 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/bofanglutide#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07628985
URL:https://assetmemo.bio/drug/bofanglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07493057-190@assetmemo.bio
DTSTAMP:20261121T004047Z
DTSTART;VALUE=DATE:20271114
DTEND;VALUE=DATE:20271115
SUMMARY:Bofanglutide: Phase 3 readout est. (NCT07493057)
DESCRIPTION:Bofanglutide\, phase 3\, Obesity.\nStudy: Evaluate the Efficacy
  and Safety of GZR18 Injection in Obese Subjects With Obstructive Sleep Ap
 nea Not Treated With Positive Airway Pressure (PAP) Therapy\nEstimated pri
 mary completion: 14 November 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/bofanglutide#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07493057
URL:https://assetmemo.bio/drug/bofanglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07622810-190@assetmemo.bio
DTSTAMP:20261121T004047Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Bofanglutide: Phase 3 readout est. (NCT07622810)
DESCRIPTION:Bofanglutide\, phase 3\, Obesity.\nStudy: BALANCE-OBS: Bofanglu
 tide (GZR18) Versus Semaglutide in Latin American Adults With Overweight o
 r Obesity\nEstimated primary completion: December 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/bofanglutide#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07622810
URL:https://assetmemo.bio/drug/bofanglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07501832-190@assetmemo.bio
DTSTAMP:20261121T004047Z
DTSTART;VALUE=DATE:20280928
DTEND;VALUE=DATE:20280929
SUMMARY:Bofanglutide: Phase 3 readout est. (NCT07501832)
DESCRIPTION:Bofanglutide\, phase 3\, Obesity.\nStudy: Evaluate the Efficacy
  and Safety of GZR18 Injection in Obese Subjects With Obstructive Sleep Ap
 nea Receiving Positive Airway Pressure (PAP) Therapy\nEstimated primary co
 mpletion: 28 September 2028. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/bofanglutide#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07501832
URL:https://assetmemo.bio/drug/bofanglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
